Trial Profile
An Open-label, Multi-center Trial to Examine the Long Term Safety, Efficacy, and Corticosteroid-sparing Effect of Certolizumab Pegol in Patients With Moderate to Severe Crohn's Disease Previously Enrolled in C87059 (COSPAR I, NCT00349752).
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 29 Oct 2014
Price :
$35
*
At a glance
- Drugs Certolizumab pegol (Primary)
- Indications Crohn's disease
- Focus Adverse reactions
- Acronyms COSPAR II
- Sponsors UCB
- 25 Jun 2014 New trial record
- 26 Feb 2010
- 18 Nov 2008